- Home
- AAME vs BCAB Comparison
AAME vs BCAB Comparison
Compare AAME & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAME
- BCAB
- Stock Information
- Founded
- AAME 1968
- BCAB 2007
- Country
- AAME United States
- BCAB United States
- Employees
- AAME N/A
- BCAB N/A
- Industry
- AAME Life Insurance
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- AAME Finance
- BCAB Health Care
- Exchange
- AAME Nasdaq
- BCAB Nasdaq
- Market Cap
- AAME 27.5M
- BCAB 27.0M
- IPO Year
- AAME N/A
- BCAB 2020
- Fundamental
- Price
- AAME $1.39
- BCAB $0.32
- Analyst Decision
- AAME
- BCAB Buy
- Analyst Count
- AAME 0
- BCAB 2
- Target Price
- AAME N/A
- BCAB $1.00
- AVG Volume (30 Days)
- AAME 21.8K
- BCAB 534.2K
- Earning Date
- AAME 05-13-2025
- BCAB 05-13-2025
- Dividend Yield
- AAME 1.43%
- BCAB N/A
- EPS Growth
- AAME N/A
- BCAB N/A
- EPS
- AAME N/A
- BCAB N/A
- Revenue
- AAME $188,227,000.00
- BCAB $11,000,000.00
- Revenue This Year
- AAME N/A
- BCAB N/A
- Revenue Next Year
- AAME N/A
- BCAB N/A
- P/E Ratio
- AAME N/A
- BCAB N/A
- Revenue Growth
- AAME 0.77
- BCAB N/A
- 52 Week Low
- AAME $1.25
- BCAB $0.24
- 52 Week High
- AAME $2.08
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- AAME 44.42
- BCAB 47.24
- Support Level
- AAME $1.30
- BCAB $0.26
- Resistance Level
- AAME $1.52
- BCAB $0.34
- Average True Range (ATR)
- AAME 0.16
- BCAB 0.04
- MACD
- AAME -0.01
- BCAB 0.00
- Stochastic Oscillator
- AAME 22.41
- BCAB 58.18
About AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.